Stock · GLAND · Healthcare
GLAND share price target 2026
Support, resistance, the F&O structure and the BazaarBaazi Crack Score for GLAND PHARMA LIMITED, refreshed every end-of-day run. A systematic, data-only read on GLAND PHARMA LIMITED: where it trades versus its 50-day and 200-day lines, the live 52-week range, and momentum, refreshed from the scanner's real price series each run.
The verdict
BazaarBaazi reads GLAND as constructive with a Crack Score of 87/100 as of 21 Jul 2026.
BazaarBaaziSource & method
The scanner's readNear-perfect · scanned 21 Jul 2026
Where GLAND stands on the 500-name BazaarBaazi setup scanner: technicals, filed fundamentals and money flow read together, refreshed every run.
One directional side cleared its price-structure, filed-evidence and signed money-flow gates with no blocking red flag.
Technical axis
100/100Fundamental axis
100/100Money flow
81/100Result pulse · Q4 FY26
100/100Named setups in force
- stage2 uptrend
- pullback to rising MA
- under accumulation
- RS leader
- earnings acceleration
- quality margins
- relative value
- growth underpriced
- result winner
Technical evidence
price above 50DMA
price above 150DMA
price above 200DMA
50 > 150 > 200 DMA (clean stack)
uptrend frame (50 > 200 DMA)
50DMA rising
pulled back to a rising MA
orderly dip from highs
money-flow score 81.0/100
Chaikin money flow +0.097 (accumulation)
up/down volume 2.43x (buyers dominant)
net +6 accumulation days (25d)
relative strength rising vs NIFTY
RS line near its highs (leadership)
RS slope +38.2% (3m)
outperforming and above 50DMA
Fundamental evidence
net profit +96.57% YoY
revenue +22.31% YoY
net margin 21.04%
result score 100.0/100
net margin 21.04% (high)
result score 100.0/100
profit not shrinking YoY
revenue +22.31% YoY
cheaper than sector (0.79x median)
bottom-half P/E within sector
relatively cheap (sector + history)
result score 100.0/100
delivering more growth than priced (gap +21)
materially underpriced growth
real growth ~47%
result score 100.0/100
result score 100.0/100 (top tier)
strong filed quarter
profit up YoY
revenue up YoY
Valuation and context
P/E 39.8 vs sector median 50.4 (0.79x, 32th pctile)
P/E 1.02x its own ~15m median (38.9)
Relative valuation
P/E (TTM)
39.8P/E vs sector
+0.8%Sector percentile
32PEG
0.41Growth gap
+20.7%P/E vs own history
+1.0%The engine's trade frame
Entry zone
2,482.4Stop
2,322.9Target 1
2,801.4Target 2
2,961.0Risk / reward
6.4% risk · 2.0RScanner levels from the deterministic engine run of 2026-07-21, not a SEBI-registered recommendation and not investment advice. The fundamental axis reads the official filing: Q4 FY26 result.
Price target: support and resistanceComputed 21 Jul 2026
Support and resistance for GLAND are read inside the latest show; no spot was printed in the most recent editorial note.
Levels are read inside the latest show. The most recent editorial reference is Systematic Read on 21 Jul 2026.
These are structural reference lines, not a SEBI-registered price target. BazaarBaazi is independent media; the levels frame how the desk reads the GLAND chart, refreshed every end-of-day run.
The Crack Score, and how it is built87 / 100 · High conviction
The Crack Score is a deterministic 0 to 100 conviction number. Here is exactly what moved it for GLAND, so the figure is a transparent signal rather than a vibe.
Base 50, adjusted by the factors above and clamped to 0 to 100. How the Crack Score works.
The F&O viewHorizon · swing
How the futures and options structure on GLAND reads right now.
The editorial price read on GLAND is bullish. Strike-level option inventory is unavailable, so the page withholds writer, wall and pin claims. Single-stock F&O on GLAND can be thinner than index F&O, so the desk weights price and filed evidence over raw OI. This is not a derivatives trade recommendation.
Why it movedLatest editorial line
The most recent BazaarBaazi read on what is driving GLAND.
Systematic read: a disclosed, data-only model on real 1-year price structure.
Read in Systematic Read on 21 Jul 2026. Why GLAND moved, the living explainer, tracks every move on one URL.
Latest filed resultsQ4 FY26
GLAND PHARMA LIMITED's most recent quarter, parsed straight from the official NSE filing. Every figure links back to its primary source.
Result Pulse
100 / 100Revenue
Rs 1,743 crNet profit
Rs 367 crEPS (quarter)
Rs 22.26| Growth | YoY | QoQ |
|---|---|---|
| Revenue | +22.3% | +2.8% |
| Net profit | +96.6% | +40.2% |
| Net margin | +21.0% | |
Figures are the Q4 FY26 result for GLAND PHARMA LIMITED, parsed straight from the official NSE integrated filing and verified to the paisa. The EPS shown is for the quarter, not a trailing-twelve-month figure, so it is not a P/E input.
Earnings history, every filed quarter22 quarters on record
GLAND PHARMA LIMITED's official quarterly revenue, EPS and Result Pulse trail, every quarter the desk holds from the verified filings export, back to 31 Dec 2020. These are quarterly facts, not TTM valuation inputs.
GLAND official result trail
22 quarters
Quarterly figures only: revenue, net profit and EPS are copied from official filings. EPS here is not trailing twelve month EPS and is not used for valuation.
| Quarter | Revenue | EPS | PAT YoY | Pulse | Source |
|---|---|---|---|---|---|
| Q4 FY26ended 31 Mar 2026 / Consolidated, audited | Rs 1,743 cr | Rs 22.26 | n/a | n/a | Filing |
| Q3 FY26ended 31 Dec 2025 / Consolidated, audited | Rs 1,695 cr | Rs 15.87 | n/a | 68/100 | Filing |
| Q2 FY26ended 30 Sep 2025 / Consolidated, audited | Rs 1,487 cr | Rs 11.15 | n/a | n/a | Filing |
| Q1 FY26ended 30 Jun 2025 / Consolidated, audited | Rs 1,506 cr | Rs 13.08 | n/a | n/a | Filing |
| Q4 FY25ended 31 Mar 2025 / Consolidated, audited | Rs 1,425 cr | Rs 11.32 | n/a | 50/100 | Filing |
| Q3 FY25ended 31 Dec 2024 / Consolidated, audited | Rs 1,384 cr | Rs 12.42 | n/a | n/a | Filing |
| Q2 FY25ended 30 Sep 2024 / Consolidated, audited | Rs 1,406 cr | Rs 9.93 | n/a | n/a | Filing |
| Q1 FY25ended 30 Jun 2024 / Consolidated, audited | Rs 1,402 cr | Rs 8.73 | n/a | n/a | Filing |
| Q4 FY24ended 31 Mar 2024 / Consolidated, audited | Rs 1,537 cr | Rs 11.68 | n/a | n/a | Filing |
| Q3 FY24ended 31 Dec 2023 / Consolidated, audited | Rs 1,545 cr | Rs 11.65 | n/a | n/a | Filing |
| Q2 FY24ended 30 Sep 2023 / Consolidated, audited | Rs 1,373 cr | Rs 11.78 | n/a | n/a | Filing |
| Q1 FY24ended 30 Jun 2023 / Consolidated, audited | Rs 1,209 cr | Rs 11.79 | n/a | n/a | Filing |
| Q4 FY23ended 31 Mar 2023 / Consolidated, audited | Rs 785 cr | Rs 4.78 | n/a | n/a | Filing |
| Q3 FY23ended 31 Dec 2022 / Consolidated, audited | Rs 938 cr | Rs 14.08 | n/a | n/a | Filing |
| Q2 FY23ended 30 Sep 2022 / Consolidated, audited | Rs 1,044 cr | Rs 14.65 | n/a | n/a | Filing |
| Q1 FY23ended 30 Jun 2022 / Consolidated, audited | Rs 857 cr | Rs 13.93 | n/a | n/a | Filing |
| Q4 FY22ended 31 Mar 2022 / Consolidated, audited | Rs 1,103 cr | Rs 17.40 | n/a | n/a | Filing |
| Q3 FY22ended 31 Dec 2021 / Consolidated, audited | Rs 1,063 cr | Rs 16.62 | n/a | n/a | Filing |
| Q2 FY22ended 30 Sep 2021 / Consolidated, audited | Rs 1,080 cr | Rs 18.37 | n/a | n/a | Filing |
| Q1 FY22ended 30 Jun 2021 / Consolidated, audited | Rs 1,154 cr | Rs 21.41 | n/a | n/a | Filing |
| Q4 FY21ended 31 Mar 2021 / Consolidated, audited | Rs 888 cr | Rs 15.93 | n/a | n/a | Filing |
| Q3 FY21ended 31 Dec 2020 / Standalone, audited | Rs 859 cr | Rs 12.83 | n/a | n/a | Filing |
The official financialsFiled to 31 Mar 2026
GLAND PHARMA LIMITED's statements as filed: trailing twelve month P&L, the balance sheet, and the cash engine. Parsed from official XBRL, shown in crore.
Trailing twelve months, on filed quarters
Revenue (TTM)
6,431 crNet profit (TTM)
1,027 crEBIT (TTM)
1,498 crProfit before tax (TTM)
1,465 crNet margin (TTM)
16.0%Finance costs (TTM)
33.3 crBalance sheet, as filed 2026-03-31
Total assets
12,511 crShareholder equity
10,358 crTotal borrowings
243 crCash and equivalents
3,359 crInventory
1,744 crTrade receivables
1,891 crThe cash engine, latest filed year
Operating cash flow
1,031 crCapex
494 crFree cash flow
537 crInvesting flow
138 crFinancing flow
-417 crAnnual trail, filed year over filed year
| Year | Revenue | Net profit | Equity | Borrowings | CFO |
|---|---|---|---|---|---|
| FY26 | 6,431 cr | 1,027 cr | 10,358 cr | 243 cr | 1,031 cr |
| FY25 | 5,617 cr | 699 cr | 9,151 cr | 269 cr | 915 cr |
| FY24 | 5,665 cr | 772 cr | 8,724 cr | 320 cr | 997 cr |
| FY23 | 3,625 cr | 781 cr | 7,959 cr | 3.8 cr | 364 cr |
| FY22 | 4,401 cr | 1,212 cr | 7,158 cr | 3.9 cr | 791 cr |
| FY21 | 3,463 cr | 997 cr | 5,903 cr | 3.9 cr | n/a |
Every figure is parsed from GLAND PHARMA LIMITED's official NSE XBRL filings by the BazaarBaazi earnings lab and shown in crore rupees. Display data, not a valuation model input.
Management on record22 earnings calls
Every GLAND earnings call BazaarBaazi has indexed, latest 31 May 2026. Read management in its own words, straight from the filed transcript.
GLAND PHARMA LIMITED earnings calls on record
22 calls since 28 Feb 2021
Show 14 older calls
Each entry links to the transcript PDF the company filed with the exchange. Primary sources, in management's own words.
What changed56 disclosures
Every recent official filing from GLAND PHARMA LIMITED, straight from the exchange feed, with the BazaarBaazi Event Heat on the disclosure flow.
GLAND PHARMA LIMITED has filed 56 official disclosures recently. The most recent is a Disclosure dated 20 Jul 2026.
Event Heat
48 / 100Certificate under SEBI (Depositories and Participants) Regulations, 2018
the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Event Heat is a dated net read of GLAND PHARMA LIMITED's last 90 days of official disclosures, balancing the constructive filings against the ones to watch. It is a signal from what the company has filed, not investment advice. Every line above links to its official exchange filing, and the full market desk is at the disclosures hub.
Key fundamentalsEditorial reference
The anchor data BazaarBaazi references when reading the GLAND chart. Not a substitute for a registered research note.
| Ticker | GLAND |
|---|---|
| Full name | GLAND PHARMA LIMITED |
| Sector | Healthcare |
| Index class | MID CAP |
| ISIN | INE068V01023 |
| Market-cap band | ~40,892 cr (indicative) |
| Last referenced level | Inside latest show |
| Last session move | Not referenced this cycle |
| Editorial line in | Systematic Read on 21 Jul 2026 |
| Aliases tracked | GLAND |
Reference chartLevels in show
The daily frame the desk reads on GLAND.
FAQ13 reader questions · AEO-eligible
The line on GLAND, distilled and schema-marked for AI Overview, Perplexity, and reader search.
What is the GLAND share price target for 2026?
BazaarBaazi does not publish a SEBI-registered price target on GLAND. The desk reads structural support and resistance inside each show against the printed spot; the most recent editorial line is Systematic Read on 21 Jul 2026.
What is BazaarBaazi's Crack Score for GLAND?
The BazaarBaazi Crack Score for GLAND is 87 out of 100 as of 21 Jul 2026, a high conviction reading. It is a computed conviction number from the signed stance, how consistent the recent verdicts have been, the quality of the printed structure, and how fresh the review is. It is a transparency signal, not investment advice.
What is the F&O view on GLAND?
Strike-level option inventory for GLAND is unavailable, so BazaarBaazi withholds participant, direction and positioning claims. The editorial chart stance is not substituted for an option-chain observation.
What sector is GLAND in and which peers does BazaarBaazi track?
GLAND sits in Healthcare (mid cap), indicative market cap ~40,892 cr (indicative), ISIN INE068V01023. The peers BazaarBaazi reads alongside it are Eris Lifesciences Limited, ACUTAAS CHEMICALS LIMITED, IPCA LABORATORIES LIMITED. A systematic, data-only read on GLAND PHARMA LIMITED: where it trades versus its 50-day and 200-day lines, the live 52-week range, and momentum, refreshed from the scanner's real price series each run.
How often is the GLAND view updated?
This page is one evergreen URL refreshed in place. The Crack Score and levels re-compute on every BazaarBaazi end-of-day run, and the dated stamp shows the last refresh. The latest signed verdict on GLAND is bullish, published in Systematic Read on 21 Jul 2026.
Is GLAND a qualifying setup on the BazaarBaazi scanner right now?
On the 2026-07-21 run of the 500-name BazaarBaazi setup scanner, GLAND PHARMA LIMITED sits in the Near-perfect tier with a setup score of 100/100 (technical 100, fundamental 100). The scanner is a deterministic engine over real OHLCV and official filings, refreshed nightly, and it is a signal rather than investment advice.
Where can I read GLAND PHARMA LIMITED's earnings call transcripts?
BazaarBaazi indexes 22 GLAND earnings calls going back to 2021-02-28, latest 2026-05-31. Every entry on this page links straight to the transcript PDF the company filed with the exchange, so you read management in the primary source.
What was GLAND PHARMA LIMITED's Q4 FY26 net profit?
GLAND PHARMA LIMITED reported a net profit of Rs 367 cr for Q4 FY26 (the quarter ended 31 March 2026). That is +96.6% year on year. The figure is from the company's official NSE filing.
What was GLAND PHARMA LIMITED's Q4 FY26 revenue?
GLAND PHARMA LIMITED reported revenue of Rs 1,743 cr for Q4 FY26. That is +22.3% year on year. The figure is from the company's official NSE filing.
How does BazaarBaazi rate GLAND PHARMA LIMITED's Q4 FY26 result?
BazaarBaazi gives GLAND PHARMA LIMITED's Q4 FY26 result a Result Pulse of 100 out of 100, with a verdict of Profit acceleration. The Result Pulse is a BazaarBaazi editorial score for the quality of the filed result, not investment advice.
What has Gland Pharma Ltd announced recently?
Gland Pharma Ltd's two most material recent disclosures are a disclosure dated 20 Jul 2026, "Change in Director(s) of the company", and a regulatory dated 13 Jul 2026, "Certificate under SEBI (Depositories and Participants)…". Both link to the company's own official filing on the BazaarBaazi stock page.
Has Gland Pharma Ltd declared a dividend recently?
Yes. Gland Pharma Ltd filed a dividend disclosure on 15 May 2026, filed as "Record date for the purpose of Dividend is 11-Aug-2026". Any amount shown is the exchange's own record, linked from the BazaarBaazi stock page. A dividend is a declared payout, not a forecast of future returns.
What did Gland Pharma Ltd's latest board meeting cover?
Gland Pharma Ltd's most recent board-meeting disclosure on record dated 15 Jun 2026 reads "Outcome of Board Meeting held on Jun 15, 2026". That is the agenda as filed with the exchange, linked from the BazaarBaazi stock page, and BazaarBaazi adds no claim of its own to it.
Related stock views
The names BazaarBaazi reads alongside GLAND, each a living view refreshed every end-of-day run.